Mayne Pharma Group Says Net Revenues Fall 5.5% Year on Year for the Period Between July, November

MT Newswires Live12-22 10:35

Mayne Pharma Group (ASX:MYX) said that during the period from July to November, its net revenues were AU$165 million, falling 5.5% from the same period in the previous year, according to a Monday Australian bourse filing.

The Women's Health sector was flat at $50.8 million while dermatology was down 12% to $37.1 million over the same period. The Women's Health sector saw continued growth with demand for total prescriptions showing continued volume growth through the first five months of fiscal year 2026.

Underlying earnings before interest, taxes, depreciation, and amortization for the period was AU$11.5 million compared to the prior-year EBITDA of AU$22.4 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment